Almost everything written about these drugs and surgery treats them as alternatives. This study treats them as a sequence, and it is the first thing this desk has seen that speaks to the order — which matters because surgery is the most durable option in the real-world literature and nobody here sells it.
What was compared
Adults who had metabolic and bariatric surgery between 2016 and 2025 in a US records database. [1] Prior use was defined as at least one GLP-1 or tirzepatide prescription between 365 and 7 days before the operation, and anybody with a prescription closer than that was excluded. Prior users and non-users were matched one to one, leaving 11,052 in each group, and followed from the first postoperative day through day 90.
That seven-day exclusion is a good design choice worth naming. It removes the separate question of whether these drugs complicate anesthesia, and leaves a cleaner question: does having been on one in the year before surgery change how the surgery goes?
What was found, both ways round
Four-point major adverse cardiovascular events occurred in 36 prior users and 67 non-users: 0.3% against 0.6%, hazard ratio 0.535, 95% CI 0.357 to 0.803. Early postoperative kidney events occurred in 158 and 256: 1.4% against 2.3%, hazard ratio 0.613, 95% CI 0.502 to 0.747. Coronary events and heart failure also came in lower.
Who takes a GLP-1 before bariatric surgery
Not a random sample of surgical candidates. Getting a prescription filled in the year before an elective operation requires a prescriber, usually insurance, and the kind of sustained engagement with care that also predicts recovering well from an operation.
Propensity matching balances what the records contain. It cannot balance conscientiousness, social support, or the quality of the practice somebody attends. That this drug reaches better-insured and higher-income patients is itself measured — income and private coverage predict who gets it — and those are the same characteristics that predict recovering well from an operation. The effect size here is modest enough to be believable; the structure is still observational.
What it does not cover
Ninety days. Nothing about weight a year later, nothing about whether the surgery worked better, nothing about whether people who took a drug first ended up needing surgery at all. The authors describe their finding as support for further investigation of preoperative metabolic optimization, which is the appropriately narrow conclusion.
The part a buyer can use
If surgery is on your list of options — and on the real-world evidence it should be — this is a reason to ask your surgical team about sequencing rather than treating the two as rival purchases. Nobody on this roster sells surgery, earns anything from it, or can advise on it.
What this site can tell you is what the drug half costs while you decide, which is in the six-month view. A year of GLP-1 before an operation is a year of the monthly figure, and that is a real number to weigh against a three-in-a-thousand difference in early complications.